simplyStocks
Explore all companies →
Pfizer
PFE · NYSEPharmaceuticals
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
Inputs &supplyAPIs, bioprocess, compone…Discovery &trialsR&D, partners, regulatorsManufacturingDrug substance, fill-fini…ProductsMedicines, therapies, dev…Payers &distributionWholesalers, PBMs, health…Providers &patientsHospitals, surgeons, pati…APIAPI & input suppliersTMOThermo FisherLONLonzaPR&TPfizer R&D & trialsBNTXBioNTech3SB3SBioFDAFDA / EMAPFEPfizerVAXComirnaty & AbrysvoCVEliquis & VyndaqelONCOncology (Seagen ADCs)PAXPaxlovidWHLDrug wholesalersPAYPayers & PBMsHOSPHospitals & pharmaciesYOUPatients
Company details
Market cap
$144B
P/E ratio
20×
Div yield
6.6%
Adj. EPS (2025)
$3.22
Net margin
12%
Rev. growth
-1%
Revenue (2025)
$62.6B
R&D spend
$10.4B
In plain English
Pfizer is one of the world's largest drugmakers — the company behind the COVID vaccine Comirnaty and the antiviral Paxlovid — now racing to refill a post-COVID revenue gap. It runs a deep heart, vaccine and cancer portfolio (Eliquis, Vyndaqel, Prevnar, Abrysvo) and has bet ~$43B on Seagen's cancer drugs and ~$10B on Metsera's obesity pipeline to power the next decade.
In simple terms
What Pfizer really sells
Pfizer is one of the world's largest drugmakers — the company behind the COVID vaccine Comirnaty and the antiviral Paxlovid — now racing to refill a post-COVID revenue gap. It runs a deep heart, vaccine and cancer portfolio (Eliquis, Vyndaqel, Prevnar, Abrysvo) and has bet ~$43B on Seagen's cancer drugs and ~$10B on Metsera's obesity pipeline to power the next decade.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
Moderate
SteadierMore speculative
Why this rating?